Biocon stock falls 4% after subsidiary sells branded formulations biz to Eris Lifesciences

Biocon Biologics said that it has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *